MarketVIEW - Chlamydia trachomatis vaccines

  • June 2012
  • -
  • VacZine Analytics Group Of Assay Advantage Ltd

Chlamydia trachomatis (CT) is an intracellular Gram-negative bacterium and a leading cause worldwide of sexually-transmitted disease and preventable blindness. The pathogen is a major cause of serious reproductive complications in the female with outcomes such as pelvic inflammatory disease (PID) and ectopic pregnancies.

Although diagnosed infections with Chlamydia trachomatis are curable with antibiotic therapy the vast majority infections are "silent" and unrecognized. This is of concern due to continued transmission especially among individuals below 30 years of age. Prophylatic vaccines could prevent CT primary infection, reinfection or lessen the incidence and severity of PID, or similar long-term sequelae. A key question for vaccine manufacturers is whether a CT vaccine would be deployed alongside HPV vaccines in the preadolescent population, thus providing a sizeable commercial opportunity.

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for a putative CT vaccine until 2035. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on new adolescent vaccines.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

Table Of Contents

MarketVIEW - Chlamydia trachomatis vaccines
Contents - Summary presentation (MS PowerPoint based)

Executive Summary
Commercial model - key outputs
Total available demand: Chlamydia vaccine, global, (000s doses)
Total available demand: Chlamydia vaccine, high-income markets, (000s doses)
Total available demand: Chlamydia vaccine, emerging markets, (000s doses)
Total available market: Chlamydia vaccine, global, ($ 000s)
Total available market: Chlamydia vaccine, by market, ($ 000s)
Total available market: Chlamydia vaccine, price sensitivity analysis, ($ 000s)
Chlamydia vaccine: country volume analysis, 2025 (000s doses)
Chlamydia vaccine: country value analysis, 2025 ($ 000s)
The role of a CT vaccine
Commercial model - key assumptions
Pricing
Model forecast comparisons: June 2011 v current
Chlamydia vaccine opportunity: target product profile
Overall commercial model assumptions per country
Chlamydia trachomatis: brief background
Clinical features
Chlamydia trachomatis: natural history of infection
Chlamydia trachomatis: global incidence
Chlamydia trachomatis: global prevalence
US epidemiology
UK epidemiology
Reasons for increasing incidence
Potential impact of a CT vaccine
Competitor landscape: overview
Competitive environment: major players
Chlamydia trachomatis vaccine - HPV, a relevant case study?
HPV vaccines: analysis of country uptake
Bibliography
Disclaimer
About VacZine Analytics

PAGES: ~57 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents - Vaccine demand model (MS Excel-based)

Title Sheet
Scenario definition
Value Scenario Analysis
Value Summary (Western)
Volume Summary (Western)
Value Summary (Emerging)
Volume Summary (Emerging)
Charts - volume (Western)
Charts - value (Western)
Charts - value/volume (Western)
Females (Western)
US (13 yrs/ 14 - 18 yrs)
Canada
UK
France
Germany
Italy
Spain
Other EU
Australia
Japan
Females (Emerging)
Brazil
Russia
India
China
Mexico
Population database
Competition - IP landscape
Assumptions - major markets
Back page
About VacZine Analytics
Disclaimer

WORKSHEETS: ~65

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Analysis of the Global Vaccines Delivery Market : Innovative Technologies and Future Trends for Stakeholders

Analysis of the Global Vaccines Delivery Market : Innovative Technologies and Future Trends for Stakeholders

  • $ 6 500
  • Industry report
  • March 2015
  • by Frost & Sullivan

Methodology The analysis in this research service is based on the following: •Information collected through discussions with market participants. •Information from secondary pharmaceutical companies, ...

Meningococcal Vaccines Market (Polysaccharide, Conjugate, Combination and Men B Vaccines, along with Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022

Meningococcal Vaccines Market (Polysaccharide, Conjugate, Combination and Men B Vaccines, along with Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022

  • $ 4 795
  • Industry report
  • April 2015
  • by Transparency Market Research

Meningococcal disease, especially meningococcal meningitis, is one of the most catastrophic infections among individuals or communities. Several meningococcal serogroups have been identified till date, ...

Global Preventable Vaccines Market 2015-2019

Global Preventable Vaccines Market 2015-2019

  • $ 3 000
  • Industry report
  • February 2015
  • by Infiniti Research Limited

About Preventable Vaccines Vaccines can be defined as a product that stimulates a person’s immune system to produce immunity to a specific disease, thereby protecting the person from that disease. According ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.